Notably, the treatments altered the gene expression of several tumorigenic and immunologic mediators, including <i>MSXI</i>, <i>ZRSR2</i>, <i>GALNTL6</i>, <i>IL24</i>, and <i>IL18R1</i>, which may impact cancer cell behavior. Here, IL18R1 is linked to cancer.